PapersPMID:34488251
Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis.
What moved
1 findingHow to read these marks →“S. repens may result in an increase in Qmax compared to placebo at 2 to 6 months follow-up (MD 1.16, 95% CI 0.47 to 1.84; 1,833 participants; 13 studies; I2=75%), however this effect dissolve at 12 to 17 month follow-up (MD 0.26, 95% CI −0.22 to 0.74; n=1,019; 5 studies; I2=0%).”
- Study
- meta-analysis
- Participants
- 1,833
- Effect
- 1.16 mean difference, 95% CI 0.47 to 1.84
- Population
- Men aged 45 years and over with lower urinary tract symptoms due to benign prostatic enlargement; main comparison, S. repens extract versus placebo; short-term follow-up 2 to 6 months, 13 pooled studies
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Men aged 45 and over with LUTS due to benign prostatic enlargement, minimum IPSS score of 8
- Participants
- 4,853
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 20